Monash University

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (2017) Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, et al. Journal article Decreasing the Wettability of Cellulose Nanocrystal Surfaces Using Wrinkle-Based Alignment (2017) Prathapan R, Berry JD, Fery A, Garnier G, Tabor RF Journal article Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes (2017) Witzel M, Petersheim D, Fan Y, Bahrami E, Racek T, Rohlfs M, Puchalka J, et al. Journal article Congenital valvular defects associated with deleterious mutations in the PLD1 gene (2017) Ta-Shma A, Zhang K, Salimova E, Zernecke A, Sieiro-Mosti D, Stegner D, Furtado M, et al. Journal article Secure SWIPT Networks Based on a Non-Linear Energy Harvesting Model (2017) Boshkovska E, Zlatanov N, Dai L, Wing Kwan Ng D, Schober R Conference contribution Erratum to: Sensitisation of TRPV4 by PAR2 is independent of intracellular calcium signalling and can be mediated by the biased agonist neutrophil elastase. (2017) Sostegni S, Diakov A, Mcintyre P, Bunnett N, Korbmacher C, Härteis S Journal article, Erratum Early CCR6 expression on B cells modulates germinal centre kinetics and efficient antibody responses (2017) Reimer D, Lee AYS, Bannan J, Fromm P, Kara EE, Comerford I, Mccoll S, et al. Journal article SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution